T2 Biosystems Inc (TTOO) Director David B. Elsbree Purchases 10,000 Shares of Stock
T2 Biosystems Inc (NASDAQ:TTOO) Director David B. Elsbree purchased 10,000 shares of the stock in a transaction dated Wednesday, March 15th. The shares were bought at an average price of $5.97 per share, with a total value of $59,700.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $238,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of T2 Biosystems Inc (NASDAQ:TTOO) traded down 4.043% on Monday, hitting $5.815. 57,408 shares of the stock traded hands. T2 Biosystems Inc has a 52 week low of $4.89 and a 52 week high of $11.30. The firm’s market cap is $177.25 million. The stock has a 50-day moving average price of $5.81 and a 200 day moving average price of $6.10.
Your IP Address:
TTOO has been the subject of several research analyst reports. Morgan Stanley downgraded shares of T2 Biosystems from an “equal weight” rating to an “underweight” rating and set a $5.00 price target for the company. in a report on Tuesday, March 14th. WBB Securities reiterated a “buy” rating and set a $12.00 price target on shares of T2 Biosystems in a report on Sunday, February 5th. Canaccord Genuity set a $9.00 price target on shares of T2 Biosystems and gave the stock a “buy” rating in a report on Tuesday, February 14th. Zacks Investment Research downgraded shares of T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, January 11th. Finally, Cantor Fitzgerald set a $7.00 price target on shares of T2 Biosystems and gave the stock a “buy” rating in a report on Wednesday, March 8th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $6.89.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TTOO. State Street Corp increased its position in T2 Biosystems by 2.7% in the fourth quarter. State Street Corp now owns 195,138 shares of the company’s stock valued at $1,027,000 after buying an additional 5,205 shares during the period. Tiger Management L.L.C. increased its position in T2 Biosystems by 5.0% in the third quarter. Tiger Management L.L.C. now owns 1,307,639 shares of the company’s stock valued at $9,467,000 after buying an additional 62,501 shares during the period. Lagoda Investment Management L.P. acquired a new position in T2 Biosystems during the third quarter valued at approximately $13,625,000. Finally, Senvest Management LLC increased its position in T2 Biosystems by 14.9% in the third quarter. Senvest Management LLC now owns 1,898,080 shares of the company’s stock valued at $13,742,000 after buying an additional 246,849 shares during the period. 68.08% of the stock is owned by institutional investors.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.